Feature Story: |
European Interventional Cardiology Market Declines in 2018 as a Result of 3 Key Market Factors |
The total European market for interventional cardiology devices was valued at approximately €1.2 billion in 2017, an apparent decrease over the previous year. The growth of the European markets for interventional cardiology devices, which historically were boosted by growing angioplasty and angiography procedure numbers, will continue to experience declines due to three major market factors.
Similar to other medical device markets, the first factor impacting the interventional cardiology market is the ...
Read full press release online
|
|
A new cardiac surgical procedure to treat mitral valve disease, which is minimally invasive, does not require open-heart surgery, and offers faster recovery, is being tested in an upcoming clinical trial.
Mitral valve disease occurs when the heart’s mitral valve — which has two flaps that open and close to allow blood to flow — cannot close or open properly.
There are two types of mitral valve disease: stenosis, when the valve does not open enough to allow sufficient blood flow; and regurgitation, when the blood leaks backward, preventing blood flow from the lungs to the rest of the body, making the heart work harder.
Without timely treatment, mitral valve disease can lead to several complications, including... read more} |
|
|
XableCath, Inc., innovators of products designed to aid in the treatment of peripheral artery disease (PAD), announced that it has been granted a second U.S. Patent, No. 9,826,995, covering its XableCath™ catheter. The patent specifically describes a catheter that controls tissue contact and has a rigid ring implement that opens a blood vessel occlusion by rotating the ring against the occlusion, thus clearing the vessel and providing access across the lesion.“Our proprietary design enables the XableCath to easily slide past an occluding atheroma through the true lumen of the vessel,” stated XableCath President and Chief Executive Officer, Lisa Dunlea. “The granting of this second patent provides broad coverage and a strong foundation for XableCath’s intellectual property portfolio and... read more} |
|
Proteon Therapeutics, Inc., a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it has completed enrollment in PATENCY-2, the second Phase 3 clinical trial of investigational vonapanitase, Proteon’s lead development candidate. Top-line data from this trial is expected in March of 2019.
PATENCY-2 is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial in patients with chronic kidney disease (CKD) receiving or expecting to receive hemodialysis and undergoing surgical creation of a radiocephalic arteriovenous fistula. The trial is designed to evaluate... read more} |
|
|
|
|